COX-2 inhibitors: a potential target for drug therapy in the management of colorectal cancer.
Colorectal cancer is currently the third most common cancer in Malaysia. Elevated expression of COX-2, an induced cyclooxygenase isoenzyme, has been seen in colonic adenomas and colorectal carcinoma. There is evidence that inhibition of this COX-2 can decrease the risk of colorectal cancer. Selective COX-2 inhibitors may have a role in reducing the risk of colorectal cancer in high-risk individuals.
Ryan
A R
AR
Rosita
A R
AR
Kamarul
A K
AK
Qureshi
A
A
D000818:Animals; D017209:Apoptosis; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D051546:Cyclooxygenase 2; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008565:Membrane Proteins; D009369:Neoplasms / Q000201:enzymology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism
D004791:Enzyme Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases